

A Study of the Efficacy and Safety of Danicamtiv in Participants With Symptomatic Genetic and Familial Dilated Cardiomyopathy

NCT07210723

| | |
|------------|------------------|
| Status | RECRUITING |
| Phase | Phase 2, Phase 3 |
| Sponsor | Kardigan, Inc. |
| Enrollment | 332 participants |

Key Eligibility Criteria

Inclusion (7)

- Has a diagnosis of DCM due to probable disease-causing variants of MYH7, TTN, or other identified genetic DCM variants, or with familial DCM
- Has New York Heart Association (NYHA) Class II-IV at Screening with stable symptoms for e1 month.
- Has at least mild left ventricular enlargement (LVE) and has adequate acoustic windows to enable accurate TTEs according to the Echocardiography Core Laboratory.
- Has a LVEF of d45%.
- Is on stable doses of maximally tolerated standard-of-care heart failure (HF) therapies reflecting current guidelines for at least 4 weeks prior to the first visit.

... and 2 more (see full listing online)

Exclusion (10)

- Has heart failure with reduced ejection (HFrEF) caused primarily by ischemic heart disease, chronic valvulopathy, or another condition, as determined by the Investigator.
- Recent (<90 days) clinically significant cardiac events, including acute coronary syndrome, hemodynamically significant epicardial coronary disease (per Investigator), coronary revascularization (percutaneous coronary intervention \[PCI\] or coronary artery bypass graft \[CABG\]), or hospitalization for heart failure/intravenous (IV) diuretic use.
- Presence of disqualifying cardiac rhythms that might interfere with reliable echocardiographic measurements of left ventricle (LV) function, as determined by the Investigator including: (a) inadequately rate-controlled atrial fibrillation, (b) ectopic beats (atrial, junctional or ventricular) of sufficient frequency (e.g. > 10% of total beats) that the participant's cardiac rhythm is irregular potentially interfering with reliable echocardiographic measurements of LV function.
- Unstable or untreated severe ventricular arrhythmia (eg, ventricular tachycardia or ventricular fibrillation).
- History of malignancy of any type within 5 years prior to Screening

... and 5 more (see full listing online)

Locations (26 total)

University of Alabama Birmingham, Birmingham, Alabama, United States
Cedars Sinai, Los Angeles, California, United States
UCSF, San Francisco, California, United States
... and 23 more locations

<https://clinicaltrials.gov/study/NCT07210723>

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at ClinicalTrials.gov. Generated by ClinicalTrialsFinder.org.